An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate;Analyse des réactions adverses potentiellement reliées à la prolactine et des valeurs anormales de prolactine au cours d'études cliniques avec le palmitate de palipéridone

Annals of Pharmacotherapy

Volumn 46, Issue 10, 2012, Pages 1322-1330

  Einarson, Thomas R ^a   Hemels, Michiel E H ^b   Nuamah, Isaac ^c   Gopal, Srihari ^c   Coppola, Danielle ^c   Hough, David ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Janssen Cilag A/S   (Denmark)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Adverse events; Drug safety; Hyperprolactinemia; Long acting injectable antipsychotic; Paliperidone palmitate; Prolactin; Schizophrenia

Indexed keywords

PALIPERIDONE; PLACEBO; PROLACTIN;

ADULT; ARTICLE; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; GENDER; HUMAN; HYPERPROLACTINEMIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SEX DIFFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPERPROLACTINEMIA; ISOXAZOLES; MALE; MIDDLE AGED; PALMITATES; PROLACTIN; YOUNG ADULT;

EID: 84867810360     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R123     Document Type: Article

References (53)

1. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperpro-lactinemia in schizophrenic patients treated with conventional antipsy-chotic medications or risperidone. Psychoneuroendocrinology 2003;28: 55-68. doi: 10.1016/S0306-4530(02)00127-0
2. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in re-sponse to antipsychotic drugs: characterization across comparative clini-cal trials. Psychoneuroendocrinology 2003;28:69-82. doi: 10.1016/S0306-4530(02)00128-2
3. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: in-sights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35. doi: 10.1038/sj.mp.4002066
4. Newman-Tancredi A, Kleven MS. Comparative pharmacology of an-tipsychotics possessing combined dopamine D2and serotonin 5-HT1Are-ceptor properties. Psychopharmacol (Berl) 2011;216:451-73. doi: 10.1007/s00213-011-2247-y
5. Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics-a review. Hum Psychopharmacol 2010;25:281-97. doi: 10.1002/hup.1116
6. Veselinoviç T, Schorn H, Vernaleken IB, Schiffl K, Klomp M, Gründer G. Impact of different antidopaminergic mechanisms on the dopaminer-gic control of prolactin secretion. J Clin Psychopharmacol 2011;31:214-20. doi: 10.1097/JCP.0b013e31820e4832
7. Windgassen KW, Wesselmann U, Monking H. Galactorrhea and hyper-prolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology 1996;33:142-6. doi: 10.1159/000119265
8. Inder WJ, Castle D. Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 2011;45:830-7. doi: 10.3109/00048674.2011.589044
9. Smith SM. The impact of hyperprolactinaemia on sexual function in pa-tients with psychosis. J Psychopharmacol 2008;22(2 suppl):63-9. doi: 10.1177/0269881107088438
10. Byerly M, Suppes T, Tran Q-V, Baker RA. Clinical implications of an-tipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007;27:639-61. doi: 10.1097/jcp.0b013e31815ac4e5
11. Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivi-ties of the pituitary dopamine system in male schizophrenic patients dur-ing treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci 2001;251:141-6.
12. Juruena MF, Pondé de Sena E, Reis de Oliveira I. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc Patient Saf 2010;2:205-11.doi: 10.2147/DHPS.S6226
13. Lee B-H, Kim Y-K. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuro-Psychopharmacol Biol Psychiatry 2006;30:658-62. doi: 10.1016/j.pnpbp.2005.11.037
14. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyper-prolactinemia in schizophrenia: association with typical and atypical an-tipsychotic treatment. J Clin Psychiatry 2004;65:1491-8.
15. Rosenbloom AL. Hyperprolactinemia with antipsychotic drugs in chil-dren and adolescents. Int J Pediatr Endocrinol 2010;1-6. doi:10.1155/2010/159402
16. European Medicines Agency. Summary of product information: Zypad-hera. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000890/WC500054429.pdf (accessed 2012 Mar 11).
17. Hill AL, Sun B, Karagianis JL, Watson SB, McDonnell DP. Dose-associ-ated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry 2011;11:28. doi:10.1186/1471-244X-11-28
18. Akhondzadeh S, Rezaei F, Larijani B, Nejatisafa A-A, Kashani L, Abbasi SH. Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schiz Res 2006;84:405-10. doi: 10.1016/j.schres.2006.02.008
19. Lostia AM, Mazzarini L, Pacchiarotti I, et al. Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug con-centration and clinical response. Ther Drug Monit 2009;31:475-81.
20. European Medicines Agency. Assessment report: Xeplion. Doc. Ref. EMA/60983/2011. Procedure no. EMEA/H/C/2105. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002105/WC500103370.pdf (accessed 2011 Dec 30).
21. European Medicines Agency. Assessment of paliperidone ER OROS tablets; 2007. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000746/WC500034928.pdf (accessed 2011 Dec 30).
22. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch MRJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005; 162:1010-2.
23. Berwaerts J, Cleton A, Rossenu S, et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol 2010;24:1011-8.
24. Nussbaum AM, Stroup TS. Oral paliperidone for schizophrenia. Cochrane Database Syst Rev 2008(2):CD006369. doi: 10.1002/14651858.CD006369.pub2
25. Li H, Rui Q, Ning X, Xu H, Gu N. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1002-8. doi: 10.1016/j.pnpbp.2011.02.001
26. Niccolai Costa AM, Silva de Lima M, de Jesus Mari J. A systematic re-view on clinical management of antipsychotic-induced sexual dysfunc-tion in schizophrenia. Sao Paulo Med J 2006;124:291-7.
27. O'Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for os-teoporosis in young women with schizophrenia? J Clin Psychopharma-col 2005;25:26-31. doi: 10.1097/01.jcp.0000150223.31007.e0
28. O'Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008;22(2 Suppl):70-5. doi: 10.1177/0269881107088439
29. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996;57:337-45.
30. Gasquet I, Tcherny-Lessenot S, Lépine J-P, Falissard B. Patient satisfac-tion with psychotropic drugs: sensitivity to change and relationship to clinical status, quality-of-life, compliance and effectiveness of treatment. Results from a nation-wide 6-month prospective study. Eur Psychiatry 2006;21:531-8. doi: 10.1016/j.eurpsy.2005.09.014
31. Buis W. Patients' opinions concerning side effects of depot neuroleptics. Am J Psychiatry 1992;149:844-5.
32. Adrianzén C, Arango-Dávila C, Martínez Araujo D, et al. Relative associa-tion of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study. Human Psychopharmacol 2010;25:439-47. doi: 10.1002/hup.1143
33. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a ran-domized, double-blind, placebo-controlled efficacy and safety study (clinicaltrials.gov identifier NCT00074477). Int J Neuropsychopharma-col 2010;13:635-47. doi: 10.1017/S1461145709990988.
34. Coppola D, Liu Y, Gopal S, et al. Long-term safety, tolerability and phar-macokinetics of paliperidone palmitate: a one-year open-label study in patients with schizophrenia (clinicaltrials.gov identifier NCT01150448). Presented at: 163rd Annual Meeting of the American Psychiatric Associ-ation, New Orleans, LA, May 22-26, 2010.
35. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-re-lapse in patients with schizophrenia: a randomized, double-blind, place-bo-controlled study (clinicaltrials.gov identifier NCT00111189). Schiz Res 2010;116:107-17. doi: 10.1016/j.schres.2009.10.026
36. Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia (clinicaltrials.gov identifier NCT00111189). J Psychopharmacol 2011;25:685-97. doi: 10.1177/0269881110372817
37. Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizo-phrenia. Int J Neuropsychopharmacol 2012;15:107-18. Erratum in Int J Neuropsychopharmacol 2012;15:119.
38. Gopal S, Hough D, Xu H, et al. Efficacy and safety of paliperidone palmi-tate in adult patients with acutely symptomatic schizophrenia: a random-ized, double-blind, placebo-controlled, dose-response study (clinicaltrials. gov identifier NCT00210548). Int Clin Psychopharmacol 2010;25:247-56. doi: 10.1097/YIC.0b013e32833948fa
39. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia (clinicaltrials.gov identifier NCT00101634). Neuropsy-chopharmacology 2010;35:2072-82. doi: 10.1038/npp.2010.79
40. Hough D, Lindenmayer J-P, Gopal S, et al. Safety and tolerability of del-toid and gluteal injections of paliperidone palmitate in schizophrenia (clinicaltrials.gov identifier NCT00119756). Prog Neuro-Psychopharma-col Biol Psychiatry 2009;33:1022-31. doi: 10.1016/j.pnpbp.2009.05.014
41. Pandina GJ, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia (clinicaltrials.gov identifier NCT00589914). Prog Neuro-Psychopharmacol Biol Psychiatry 2011;35:218-26. doi: 10.1016/j.pnpbp.2010.11.008
42. Pandina GJ, Lindenmayer J-P, Lull JM, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperi-done palmitate in adults with acutely exacerbated schizophrenia (clinical-trials.gov identifier NCT00590577). J Clin Psychopharmacol 2010;30: 235-44. doi: 10.1097/JCP.0b013e3181dd3103
43. MedDra MSSO. Medical dictionary for regulatory activities maintenance and support services organization. www.meddramsso.com (accessed 2011 Dec 30).
44. European Medicines Agency.ICH Topic E2A: Clinical safety data manage-ment: definitions and standards for expedited reporting (CPMP/ICH/377/95), June 1995. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002749.pdf (accessed 2011 Dec 30).
45. FDA Center for Drug Evaluation and Research. Attachment B: clinical safety review of an NDA or BLA of the good review practice: clinical review template (MAPP 6010.3 Rev. 1); Dec 15, 2010. www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ManualofPoliciesProcedures/UCM236905.pdf (ac-cessed 2011 Dec 30).
46. Knegtering H, van den Bosch R, Castelein S, Bruggeman R, Sytema S, van Os J. Are sexual side effects of prolactin-raising antipsychotics re-ducible to serum prolactin? Psychoneuroendocrinology 2008;33:711-7. doi: 10.1016/j.psyneuen.2008.02.008
47. Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. Improvement in hyperpro-lactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006;31:577-88. doi: 10.1016/j.psyneuen.2005.12.006
48. Skopek M, Manoj P. Hyperprolactinaemia during treatment with paliperidone. Australasian Psychiatry 2010;18:261-3. doi: 10.3109/10398561003686763
49. Yoshimura R, Nakamura J, Ueda N, Terao T. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical im-provement. Int Clin Psychopharmacol 2000;15:175-80.
50. Yoshimura R, Ueda N, Nakamura J. Possible relationship between com-bined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study. Neuropsychobiology 2001;44:129-33.
51. Kakihara S, Yoshimura R, Shinkai K, et al. Prediction of response to risperidone treatment with respect to plasma concentrations of risperi-done, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005;20:71-8.
52. Spina E, Avenoso A, Facciolà G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical re-sponse in patients with schizophrenia. Psychopharmacology (Berl) 2001; 153:238-43.
53. Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998;20:380-4.